Litcius/Paper detail

Immunoreactive peptide maps of SARS-CoV-2

Nischay Mishra, Xi Huang, Shreyas Joshi, Cheng Guo, James Ng, Riddhi Thakkar, Yongjian Wu, Xin Dong, Qianlin Li, Richard S. Pinapati, Eric Sullivan, Adrian Caciula, Rafal Tokarz, Thomas Briese, Jiahai Lu, W. Ian Lipkin

2021Communications Biology76 citationsDOIOpen Access PDF

Abstract

Serodiagnosis of SARS-CoV-2 infection is impeded by immunological cross-reactivity among the human coronaviruses (HCoVs): SARS-CoV-2, SARS-CoV-1, MERS-CoV, OC43, 229E, HKU1, and NL63. Here we report the identification of humoral immune responses to SARS-CoV-2 peptides that may enable discrimination between exposure to SARS-CoV-2 and other HCoVs. We used a high-density peptide microarray and plasma samples collected at two time points from 50 subjects with SARS-CoV-2 infection confirmed by qPCR, samples collected in 2004-2005 from 11 subjects with IgG antibodies to SARS-CoV-1, 11 subjects with IgG antibodies to other seasonal human coronaviruses (HCoV), and 10 healthy human subjects. Through statistical modeling with linear regression and multidimensional scaling we identified specific peptides that were reassembled to identify 29 linear SARS-CoV-2 epitopes that were immunoreactive with plasma from individuals who had asymptomatic, mild or severe SARS-CoV-2 infections. Larger studies will be required to determine whether these peptides may be useful in serodiagnostics.

Topics & Concepts

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakGeographyComputer scienceMedicineInternal medicineInfectious disease (medical specialty)DiseaseOutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studiesvaccines and immunoinformatics approaches
Immunoreactive peptide maps of SARS-CoV-2 | Litcius